;PMID: 9036183
;source_file_930.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..225] = [t:46..225]
;2)section:[e:229..292] = [t:229..292]
;3)section:[e:296..389] = [t:296..389]
;4)sentence:[e:393..620] = [t:393..620]
;5)sentence:[e:621..763] = [t:621..763]
;6)sentence:[e:764..958] = [t:764..958]
;7)sentence:[e:959..1043] = [t:959..1043]
;8)sentence:[e:1044..1273] = [t:1044..1273]
;9)sentence:[e:1274..1450] = [t:1274..1450]
;10)sentence:[e:1451..1581] = [t:1451..1581]
;11)sentence:[e:1582..1823] = [t:1582..1823]
;12)sentence:[e:1824..1908] = [t:1824..1908]
;13)section:[e:1912..1956] = [t:1912..1956]

;section 0 Span:0..40
;J Pharm Pharmacol. 1996 Sep;48(9):925-9.
(SEC (NNP:[0..1] J) (NNP:[2..7] Pharm) (NNP:[8..17] Pharmacol) (.:[17..18] .)
     (CD:[19..23] 1996) (CC:[24..31] Sep;48-LRB-) (CD:[31..32] 9)
     (-RRB-:[32..33] -RRB-) (CD:[33..37] :925) (::[37..38] -) (CD:[38..40] 9.))

;sentence 1 Span:46..225
;Regioselectivity and substrate concentration-dependency of involvement of the
; CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline
;in  rat liver microsomes.
;[67..76]:substance:"substrate"
;[125..130]:cyp450:"CYP2D"
;[168..181]:substance:"amitriptyline"
;[186..199]:substance:"nortriptyline"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[46..62] Regioselectivity))
      (CC:[63..66] and)
      (NP
        (NML (NN:[67..76] substrate) (NN:[77..90] concentration))
        (HYPH:[90..91] -) (NN:[91..101] dependency)))
    (PP (IN:[102..104] of)
      (NP
        (NP (NN:[105..116] involvement))
        (PP (IN:[117..119] of)
          (NP (DT:[120..123] the) (NN:[125..130] CYP2D)
              (NN:[131..140] subfamily)))
        (PP (IN:[141..143] in)
          (NP
            (NP (JJ:[144..153] oxidative) (NN:[154..164] metabolism))
            (PP (IN:[165..167] of)
              (NP (NN:[168..181] amitriptyline) (CC:[182..185] and)
                  (NN:[186..199] nortriptyline)))))))
    (PP-LOC (IN:[200..202] in)
      (NP (NN:[204..207] rat) (NN:[208..213] liver) (NNS:[214..224] microsomes)))
    (.:[224..225] .)))

;section 2 Span:229..292
;Masubuchi Y, Iwasa T, Fujita S, Suzuki T, Horie T, Narimatsu S.
(SEC
  (FRAG (NNP:[229..238] Masubuchi) (NNP:[239..240] Y) (,:[240..241] ,)
        (NNP:[242..247] Iwasa) (NNP:[248..249] T) (,:[249..250] ,)
        (NNP:[251..257] Fujita) (NNP:[258..260] S,) (NNP:[261..267] Suzuki)
        (NNP:[268..269] T) (,:[269..270] ,) (NNP:[271..276] Horie)
        (NNP:[277..278] T) (,:[278..279] ,) (NNP:[280..289] Narimatsu)
        (NNP:[290..292] S.)))

;section 3 Span:296..389
;Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Chiba 
;University, Japan.
(SEC
  (FRAG (NN:[296..306] Laboratory) (IN:[307..309] of)
        (NNP:[310..326] Biopharmaceutics) (,:[326..327] ,)
        (NNP:[328..335] Faculty) (IN:[336..338] of)
        (NNP:[339..353] Pharmaceutical) (NNPS:[354..362] Sciences)
        (,:[362..363] ,) (NNP:[364..369] Chiba) (NNP:[371..381] University)
        (,:[381..382] ,) (NNP:[383..388] Japan) (.:[388..389] .)))

;sentence 4 Span:393..620
;Kinetic analysis of the metabolism of amitriptyline and nortriptyline using 
;liver microsomes from Wister rats showed that more than one enzyme was
;involved  in each reaction except for monophasic amitriptyline
;N-demethylation.
;[431..444]:substance:"amitriptyline"
;[449..462]:substance:"nortriptyline"
;[530..536]:substance:"enzyme"
;[590..603]:substance:"amitriptyline"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[393..400] Kinetic) (NN:[401..409] analysis))
        (PP (IN:[410..412] of)
          (NP
            (NP (DT:[413..416] the) (NN:[417..427] metabolism))
            (PP (IN:[428..430] of)
              (NP (NN:[431..444] amitriptyline) (CC:[445..448] and)
                  (NN:[449..462] nortriptyline))))))
      (VP (VBG:[463..468] using)
        (NP
          (NP (NN:[470..475] liver) (NNS:[476..486] microsomes))
          (PP (IN:[487..491] from)
            (NP (NNP:[492..498] Wister) (NNS:[499..503] rats))))))
    (VP (VBD:[504..510] showed)
      (SBAR (IN:[511..515] that)
        (S
          (NP-SBJ-1
            (QP (JJR:[516..520] more) (IN:[521..525] than) (CD:[526..529] one))
            (NN:[530..536] enzyme))
          (VP (VBD:[537..540] was)
            (VP (VBN:[541..549] involved)
              (NP-1 (-NONE-:[549..549] *))
              (PP-CLR (IN:[551..553] in)
                (NP (DT:[554..558] each) (NN:[559..567] reaction)))
              (PP (IN:[568..574] except) (IN:[575..578] for)
                (NP (JJ:[579..589] monophasic) (NN:[590..603] amitriptyline)
                    (NN:[604..619] N-demethylation))))))))
    (.:[619..620] .)))

;sentence 5 Span:621..763
;The Vmax  values particularly in the high-affinity sites for
;E-10-hydroxylation of both  drugs were larger than those for
;Z-10-hydroxylations.
;[625..629]:quantitative-name:"Vmax"
;[710..715]:substance:"drugs"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[621..624] The) (NN:[625..629] Vmax) (NNS:[631..637] values))
      (PP
        (ADVP (RB:[638..650] particularly))
        (IN:[651..653] in)
        (NP
          (NP (DT:[654..657] the)
            (NML (JJ:[658..662] high) (HYPH:[662..663] -)
                 (NN:[663..671] affinity))
            (NNS:[672..677] sites))
          (PP (IN:[678..681] for)
            (NP
              (NP (NN:[682..700] E-10-hydroxylation))
              (PP (IN:[701..703] of)
                (NP (DT:[704..708] both) (NNS:[710..715] drugs))))))))
    (VP (VBD:[716..720] were)
      (ADJP-PRD
        (ADJP (JJR:[721..727] larger))
        (PP (IN:[728..732] than)
          (NP
            (NP (DT:[733..738] those))
            (PP (IN:[739..742] for)
              (NP (NNS:[743..762] Z-10-hydroxylations)))))))
    (.:[762..763] .)))

;sentence 6 Span:764..958
;Their E- and  E-10-hydroxylase activities in Dark-Agouti rats, which are
;deficient for CYP2D1,  were significantly lower than those in Wistar rats at
;a lower substrate  concentration (5 microM).
;[770..772]...[783..794]:substance:"E-"..."hydroxylase"
;[778..794]:substance:"E-10-hydroxylase"
;[851..857]:cyp450:"CYP2D1"
;[922..931]:substance:"substrate"
;[948..949]:quantitative-value:"5"
;[950..956]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (PRP$:[764..769] Their)
        (NML
          (NML (NN:[770..771] E) (HYPH:[771..772] -)
            (NML-2 (-NONE-:[772..772] *P*)))
          (NML-3 (-NONE-:[772..772] *P*)))
        (CC:[773..776] and)
        (NML
          (NML (NN:[778..782] E-10) (HYPH:[782..783] -)
            (NML-2 (NN:[783..794] hydroxylase)))
          (NML-3 (NNS:[795..805] activities))))
      (PP-LOC (IN:[806..808] in)
        (NP
          (NP
            (NML (JJ:[809..813] Dark) (HYPH:[813..814] -) (NN:[814..820] Agouti))
            (NNS:[821..825] rats))
          (,:[825..826] ,)
          (SBAR
            (WHNP-1 (WDT:[827..832] which))
            (S
              (NP-SBJ-1 (-NONE-:[832..832] *T*))
              (VP (VBP:[833..836] are)
                (ADJP-PRD (JJ:[837..846] deficient)
                  (PP (IN:[847..850] for)
                    (NP (NN:[851..857] CYP2D1))))))))))
    (,:[857..858] ,)
    (VP (VBD:[860..864] were)
      (ADJP-PRD
        (ADJP (RB:[865..878] significantly) (JJR:[879..884] lower))
        (PP (IN:[885..889] than)
          (NP
            (NP (DT:[890..895] those))
            (PP-LOC (IN:[896..898] in)
              (NP
                (NP (NNP:[899..905] Wistar) (NNS:[906..910] rats))
                (PP (IN:[911..913] at)
                  (NP
                    (NP (DT:[914..915] a) (JJR:[916..921] lower)
                        (NN:[922..931] substrate) (NN:[933..946] concentration))
                    (PRN (-LRB-:[947..948] -LRB-)
                      (NP (CD:[948..949] 5) (NN:[950..956] microM))
                      (-RRB-:[956..957] -RRB-))))))))))
    (.:[957..958] .)))

;sentence 7 Span:959..1043
;The strain difference was reduced at a higher  substrate concentration (500
;microM).
;[1006..1015]:substance:"substrate"
;[1031..1034]:quantitative-value:"500"
;[1035..1041]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1 (DT:[959..962] The) (NN:[963..969] strain)
              (NN:[970..980] difference))
    (VP (VBD:[981..984] was)
      (VP (VBN:[985..992] reduced)
        (NP-1 (-NONE-:[992..992] *))
        (PP (IN:[993..995] at)
          (NP
            (NP (DT:[996..997] a) (JJR:[998..1004] higher)
                (NN:[1006..1015] substrate) (NN:[1016..1029] concentration))
            (PRN (-LRB-:[1030..1031] -LRB-)
              (NP (CD:[1031..1034] 500) (NN:[1035..1041] microM))
              (-RRB-:[1041..1042] -RRB-))))))
    (.:[1042..1043] .)))

;sentence 8 Span:1044..1273
;A similar but a smaller strain difference  was also observed in nortriptyline
;N-demethylase activity, and a pronounced sex  difference (male > female) was
;observed in N-demethylation of both drugs in  Wistar and Dark-Agouti rats.
;[1108..1135]:substance:"nortriptyline N-demethylase"
;[1235..1240]:substance:"drugs"
(SENT
  (S
    (S
      (NP-SBJ-3 (DT:[1044..1045] A)
        (ADJP
          (ADJP (JJ:[1046..1053] similar))
          (CC:[1054..1057] but)
          (ADJP (DT:[1058..1059] a) (JJR:[1060..1067] smaller)))
        (NN:[1068..1074] strain) (NN:[1075..1085] difference))
      (VP (VBD:[1087..1090] was)
        (ADVP (RB:[1091..1095] also))
        (VP (VBN:[1096..1104] observed)
          (NP-3 (-NONE-:[1104..1104] *))
          (PP-LOC (IN:[1105..1107] in)
            (NP
              (NML (NN:[1108..1121] nortriptyline)
                   (NN:[1122..1135] N-demethylase))
              (NN:[1136..1144] activity))))))
    (,:[1144..1145] ,) (CC:[1146..1149] and)
    (S
      (NP-SBJ-2 (DT:[1150..1151] a) (JJ:[1152..1162] pronounced)
                (NN:[1163..1166] sex) (NN:[1168..1178] difference)
        (PRN (-LRB-:[1179..1180] -LRB-)
          (S
            (NP-SBJ (JJ:[1180..1184] male))
            (VP (SYM:[1185..1186] >)
              (NP (JJ:[1187..1193] female))))
          (-RRB-:[1193..1194] -RRB-)))
      (VP (VBD:[1195..1198] was)
        (VP (VBN:[1199..1207] observed)
          (NP-2 (-NONE-:[1207..1207] *))
          (PP-LOC (IN:[1208..1210] in)
            (NP
              (NP (NN:[1211..1226] N-demethylation))
              (PP (IN:[1227..1229] of)
                (NP (DT:[1230..1234] both) (NNS:[1235..1240] drugs)))
              (PP-LOC (IN:[1241..1243] in)
                (NP
                  (NP (NNP:[1245..1251] Wistar)
                    (NML-1 (-NONE-:[1251..1251] *P*)))
                  (CC:[1252..1255] and)
                  (NP
                    (NML (JJ:[1256..1260] Dark) (HYPH:[1260..1261] -)
                         (NN:[1261..1267] Agouti))
                    (NML-1 (NNS:[1268..1272] rats))))))))))
    (.:[1272..1273] .)))

;sentence 9 Span:1274..1450
;The reactions with the strain difference were  inhibited
;concentration-dependently by sparteine, a substrate of the CYP2D  subfamily,
;and an antibody against a CYP2D isoenzyme.
;[1360..1369]:substance:"sparteine"
;[1373..1382]:substance:"substrate"
;[1390..1395]:cyp450:"CYP2D"
;[1415..1423]:substance:"antibody"
;[1434..1449]:cyp450:"CYP2D isoenzyme"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1274..1277] The) (NNS:[1278..1287] reactions))
      (PP (IN:[1288..1292] with)
        (NP (DT:[1293..1296] the) (NN:[1297..1303] strain)
            (NN:[1304..1314] difference))))
    (VP (VBD:[1315..1319] were)
      (VP (VBN:[1321..1330] inhibited)
        (NP-1 (-NONE-:[1330..1330] *))
        (ADVP-MNR (NN:[1331..1344] concentration) (HYPH:[1344..1345] -)
                  (RB:[1345..1356] dependently))
        (PP (IN:[1357..1359] by)
          (NP-LGS
            (NP (NN:[1360..1369] sparteine))
            (,:[1369..1370] ,)
            (NP
              (NP
                (NP (DT:[1371..1372] a) (NN:[1373..1382] substrate))
                (PP (IN:[1383..1385] of)
                  (NP (DT:[1386..1389] the) (NN:[1390..1395] CYP2D)
                      (NN:[1397..1406] subfamily))))
              (,:[1406..1407] ,) (CC:[1408..1411] and)
              (NP
                (NP (DT:[1412..1414] an) (NN:[1415..1423] antibody))
                (PP (IN:[1424..1431] against)
                  (NP (DT:[1432..1433] a)
                     (NN:[1434..1439] CYP2D) (NN:[1440..1449] isoenzyme)))))))))
    (.:[1449..1450] .)))

;sentence 10 Span:1451..1581
;The profiles of these  decreased metabolic activities corresponded to that of
;the lower metabolic  activities in Dark-Agouti rats.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1451..1454] The) (NNS:[1455..1463] profiles))
      (PP (IN:[1464..1466] of)
        (NP (DT:[1467..1472] these) (VBN:[1474..1483] decreased)
            (JJ:[1484..1493] metabolic) (NNS:[1494..1504] activities))))
    (VP (VBD:[1505..1517] corresponded)
      (PP-CLR (TO:[1518..1520] to)
        (NP
          (NP (DT:[1521..1525] that))
          (PP (IN:[1526..1528] of)
            (NP
              (NP (DT:[1529..1532] the) (JJR:[1533..1538] lower)
                  (JJ:[1539..1548] metabolic) (NNS:[1550..1560] activities))
              (PP (IN:[1561..1563] in)
                (NP
                  (NML (JJ:[1564..1568] Dark) (HYPH:[1568..1569] -)
                       (NN:[1569..1575] Agouti))
                  (NNS:[1576..1580] rats))))))))
    (.:[1580..1581] .)))

;sentence 11 Span:1582..1823
;These results indicated that a cytochrome P450  isozyme in the CYP2D
;subfamily was involved in E- and Z-10-hydroxylations of  amitriptyline and
;nortriptyline in rat liver microsomes as a major isozyme in a  low substrate
;concentration range.
;[1613..1637]:cyp450:"cytochrome P450  isozyme"
;[1645..1650]:cyp450:"CYP2D"
;[1708..1721]:substance:"amitriptyline"
;[1726..1739]:substance:"nortriptyline"
;[1775..1782]:cyp450:"isozyme"
;[1793..1802]:substance:"substrate"
(SENT
  (S
    (NP-SBJ (DT:[1582..1587] These) (NNS:[1588..1595] results))
    (VP (VBD:[1596..1605] indicated)
      (SBAR (IN:[1606..1610] that)
        (S
          (NP-SBJ-2
            (NP (DT:[1611..1612] a)
              
              (NML (NN:[1613..1623] cytochrome) (NN:[1624..1628] P450))
              (NN:[1630..1637] isozyme))
            (PP-LOC (IN:[1638..1640] in)
              (NP (DT:[1641..1644] the) (NN:[1645..1650] CYP2D)
                  (NN:[1651..1660] subfamily))))
          (VP (VBD:[1661..1664] was)
            (VP (VBN:[1665..1673] involved)
              (NP-2 (-NONE-:[1673..1673] *))
              (PP-CLR (IN:[1674..1676] in)
                (NP
                  (NP
                    (NP (NN:[1677..1678] E) (HYPH:[1678..1679] -)
                      (NML-1 (-NONE-:[1679..1679] *P*)))
                    (CC:[1680..1683] and)
                    (NP (NN:[1684..1685] Z) (HYPH:[1685..1686] -)
                      (NML-1 (NNS:[1686..1703] 10-hydroxylations))))
                  (PP (IN:[1704..1706] of)
                    (NP (NN:[1708..1721] amitriptyline) (CC:[1722..1725] and)
                        (NN:[1726..1739] nortriptyline)))
                  (PP-LOC (IN:[1740..1742] in)
                    (NP (NN:[1743..1746] rat) (NN:[1747..1752] liver)
                        (NNS:[1753..1763] microsomes)))))
              (PP-MNR (IN:[1764..1766] as)
                (NP
                  (NP (DT:[1767..1768] a) (JJ:[1769..1774] major)
                      (NN:[1775..1782] isozyme))
                  (PP-LOC (IN:[1783..1785] in)
                    (NP (DT:[1786..1787] a) (JJ:[1789..1792] low)
                      (NML (NN:[1793..1802] substrate)
                           (NN:[1803..1816] concentration))
                      (NN:[1817..1822] range))))))))))
    (.:[1822..1823] .)))

;sentence 12 Span:1824..1908
;It seems likely that the CYP2D enzyme  contributes to nortriptyline
;N-demethylation.
;[1849..1861]:cyp450:"CYP2D enzyme"
;[1878..1891]:substance:"nortriptyline"
(SENT
  (S
    (NP-SBJ
      (NP (PRP:[1824..1826] It))
      (SBAR-1 (-NONE-:[1826..1826] *EXP*)))
    (VP (VBZ:[1827..1832] seems)
      (ADJP-PRD (JJ:[1833..1839] likely)
        (SBAR-1 (IN:[1840..1844] that)
          (S
            (NP-SBJ (DT:[1845..1848] the)
               (NN:[1849..1854] CYP2D) (NN:[1855..1861] enzyme))
            (VP (VBZ:[1863..1874] contributes)
              (PP-CLR (TO:[1875..1877] to)
                (NP (NN:[1878..1891] nortriptyline)
                    (NN:[1892..1907] N-demethylation))))))))
    (.:[1907..1908] .)))

;section 13 Span:1912..1956
;PMID: 9036183 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1912..1916] PMID) (::[1916..1917] :) (CD:[1918..1925] 9036183)
        (NN:[1926..1927] -LSB-) (NNP:[1927..1933] PubMed) (::[1934..1935] -)
        (NN:[1936..1943] indexed) (IN:[1944..1947] for)
        (NNP:[1948..1956] MEDLINE-RSB-)))
